Trial set to see if drug can prevent Alzheimer's

May 16, 2012 in Alzheimer's disease & dementia

Trial set to see if drug can prevent alzheimer's

Many of the study participants are genetically prone to the disease.

(HealthDay) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

The best-scenario hope is that the drug will lead to a way of preventing the progressive brain-wasting disease, and to a better understanding of its destructive processes, U.S. officials announced Tuesday.

The study volunteers will include some Americans as well as 300 members of an extended Colombian family -- some only 30 years old -- thought to have more relatives with Alzheimer's than any family in the world, The New York Times reported.

None of the will have any signs of dementia at the start of the five-year, $100 million study. Dr. Francis Collins, director of the U.S. National Institutes of Health, said this study is "the first to focus on people who are cognitively normal but at very high risk for Alzheimer's disease," according to the Times.

People with a certain genetic mutation are predestined to develop early-onset Alzheimer's. For this group, dementia typically sets in by about age 50, and signs of thinking and are evident by age 45.

It's hoped that the study will reveal clues to the development and treatment of Alzheimer's -- the leading cause of dementia -- in other people as well, not just those with what doctors call early-onset Alzheimer's.

The trial is designed to test the widely held theory that Alzheimer's is caused by a buildup in the brain of a protein called . The -- crenezumab, which is made by Genentech of South San Francisco -- is designed to attack the formation of beta .

Currently, there is no cure for Alzheimer's, which affects 5.4 million Americans, or one in eight . And as the ages, those numbers are expected to balloon, creating a major public health crisis in the United States.

Experts on Alzheimer's disease welcomed the announcement of the drug trial.

"This strategy is our best chance of success at Alzheimer's disease," said Dr. Sam Gandy, associate director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine and director of Mount Sinai's Center for Cognitive Health, in New York City.

"The main challenges are how to identify who is on their way to [Alzheimer's disease], how early we need to begin prior to symptoms, and how long we will have to run the trial before we can see whether the drug delays onset," added Gandy, chairman emeritus of the Alzheimer's Association's National Medical and Scientific Advisory Council.

More information: For more about Alzheimer's disease, visit the Alzheimer's Association.

Copyright © 2012 HealthDay. All rights reserved.

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Study finds that sleep apnea and Alzheimer's are linked

A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.

Alzheimer's disease & dementia created 48 minutes ago | popularity not rated yet | comments 0 | with audio podcast

Alzheimer's leaves bilingual victims stranded in Canada

The devastating effect of Alzheimer's disease on bilingual people has been thrown into focus in Canada, where the sudden loss of a second language can leave sufferers feeling like strangers in their own country.

Alzheimer's disease & dementia created 3 hours ago | popularity not rated yet | comments 0

Study identifies new approach to improving treatment for MS and other conditions

(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...

Alzheimer's disease & dementia created May 17, 2013 | popularity 5 / 5 (2) | comments 0 | with audio podcast

Nonmelanoma skin cancer tied to lower Alzheimer's risk

(HealthDay)—Older individuals with nonmelanoma skin cancer (NMSC) seem to have a significantly reduced risk of developing Alzheimer's disease (AD), according to a study published online May 15 in Neurology.

Alzheimer's disease & dementia created May 16, 2013 | popularity 5 / 5 (1) | comments 0

Skin cancer may be linked to lower risk of Alzheimer's disease

People who have skin cancer may be less likely to develop Alzheimer's disease, according to new research published in the May 15, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. The li ...

Alzheimer's disease & dementia created May 15, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast


Researchers identify a potential new risk for sleep apnea: Asthma

Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...

Ginger compounds may be effective in treating asthma symptoms

Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...

Computational tool translates complex data into simplified 2-dimensional images

In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...

New theory on genesis of osteoarthritis comes with successful therapy in mice

Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...

'Gap' for HIV vaccine efforts after latest setback

The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.

Consuming coffee linked to lower risk of detrimental liver disease, study finds

Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...